Motexafin gadolinium

Drug Profile

Motexafin gadolinium

Alternative Names: API-GP3; FP-GP1; Gadolinium (III) texaphyrin; Gadolinium texaphyrin; Gd-Tex; Gd-texaphyrin; GdT2B2; MGd; PCI-0120; Xcytrin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacyclics
  • Class Antineoplastics; Lanthanoid series elements; Metallotexaphyrins; Small molecules
  • Mechanism of Action Thioredoxin reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Brain cancer; Cardiovascular disorders; Chronic lymphocytic leukaemia; Glioblastoma; Glioma; Head and neck cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Renal cancer; Solid tumours

Most Recent Events

  • 01 Mar 2014 Pharmacyclics terminates a phase II trial in Chronic lymphocytic leukaemia and small lymphocytic lymphoma in USA (NCT00100711)
  • 13 Jun 2008 Final efficacy data from a phase I/II trial in non-Hodgkin's lymphoma released by Pharmacyclics
  • 21 Dec 2007 Pharmacyclics receives non-approvable letter from the FDA for motexafin gadolinium in combination with radiation for brain metastases arising from non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top